The FDA has issued its long-awaited finalized guidance for industry on the development of abuse-deterrent opioids. The guidance has been a work in progress since an initial draft was released over two years ago (January 2013) and addresses the types of studies needed to establish abuse-deterrence and how those studies should be performed and evaluated. Additionally, the guidance delineates the acceptable labeling claims for abuse-deterrent drugs after the required studies have been performed. There will be four labels corresponding to different categories. Category placement depends upon the level of evidence for each opioid’s abuse-deterrent properties. Importantly, the guidance does not mandate that all new opioids must be abuse deterrent.